ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

ImmunityBio, Inc.NASDAQ: IBRX

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables declines year over year

Q3 FY2026 accounts receivables of $126K (cash outflow) fell 98.7% year over year, behind the -22.5% change in trailing-twelve-month accounts receivables. Sequentially, it fell 98.8% from the prior quarter.

Context

  • Accounts receivables amounted to 35.5% of revenue in FY2025, up 19.5 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.7% toward the trailing-twelve-month pace of -22.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$126K-98.8% QoQ
Last fiscal yearDec 2025
-$40.21M+1603.9% YoY
LTMSep 2026
-$21.58M-22.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.7%——
1 year+1603.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(40.21M) USD
Year-over-year change
-1603.9%

Accounts Receivables vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -22.5% is the 7th highest of 9, against a peer median of +174.7%.
  • Accounts receivables amounts to 11.8% of revenue for IBRX, versus a peer median of 9.9%.
IBRX Competitors
Accounts Receivables for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.89B EUR+210.6%-38.0%71.6%
MRNAModerna, Inc.LTM Sep 2026$325M USD-164.6%-55.7%12.9%
LEGNLegend Biotech CorporationLTM Sep 2026$125.44M USD+174128.2%—9.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$40.23M USD+265.9%—10.6%
IBRXImmunityBio, Inc.LTM Sep 2026$21.58M USD-22.5%—11.8%
IMCRImmunocore Holdings plcLTM Mar 2026$16.59M USD+211.8%-40.8%4.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$8.88M USD-67.1%—38.4%
IMTXImmatics N.V.LTM Mar 2026€1.5M EUR+138.9%-18.5%4.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD———
NKTXNkarta, Inc.LTM Mar 2026$0 USD———
Peer median (excluding IBRX) —+174.7%-39.4%9.9%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(346.79M)(416.57M)(583.85M)(413.65M)(351.47M)
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
Deferred Income Tax00000
Stock-Based Compensation57.18M40.18M49.16M34.43M36.81M
Change in Working Capital(15.4M)(16M)3.83M(19.42M)(54.33M)
Accounts Receivables000(2.36M)(40.21M)
Inventory000(8.27M)(6.33M)
Accounts Payables00(6.48M)(3.17M)(190K)
Other Working Capital(15.4M)(16M)10.3M(5.62M)(7.6M)
Other Non-Cash Items16.35M36.62M145.44M(10.16M)48.53M
Operating Cash Flow(274.42M)(337.51M)(366.76M)(391.24M)(304.94M)
Capital Expenditures(33.56M)(78.16M)(30.58M)(6.89M)(3.85M)
Acquisitions (Net)000(1M)0
Purchases of Investments00(10.36M)(140.22M)(241.37M)
Sales of Investments0010.47M136.61M95.82M
Other Investing Activities(51.32M)105.46M0(747K)0
Investing Cash Flow(84.89M)27.3M(30.47M)(12.25M)(149.8M)
Debt Repayment338.5M174.07M451.39M96.89M1.72M
Common Stock Issued00110.4M111.36M400.78M
Common Stock Repurchased(4.06M)(616K)000
Dividends Paid00000
Other Financing Activities171.01M60.16M(3.44M)73.38M(2.27M)
Financing Cash Flow505.44M233.61M558.34M281.63M400.24M
Effect of Forex Changes48K284K(292K)(23K)15K
Net Change in Cash146.19M(76.32M)160.82M(121.88M)(54.48M)
Free Cash Flow(307.98M)(415.67M)(397.34M)(398.12M)(308.78M)

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.